Bayer's diversified portfolio and strong pharmaceutical pipeline are expected to stabilize revenues despite concerns over loss of exclusivity, particularly with Xarelto. The Crop Sciences division has significant upside potential despite ongoing litigation. High leverage ratio limits capital allocation options.